Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis ... Phase 2 data for VX-548 ...

Vertex is just a few weeks away from hearing the FDA's verdict on its cystic fibrosis (CF) therapy Orkambi, so the publication of clinical trial data in a prestigious journal comes at an opportune ...

Any lingering doubts over the feasibility of rolling out population-based cancer registries in low-income and middle-income ...

She will be advocating for the American Heart Association’s Go RED for Women initiative, as well as cystic fibrosis research ... health so we can combat these statistics," she said.

We thank the UK CF Registry team and the UK CF centres and clinics for submitting data to the Registry. Special thanks to the people with cystic fibrosis and their families who have agreed for their ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

Learn about cystic fibrosis ... our understanding of cystic fibrosis every day, helping to shape clinical care practices for people living with the disease for years to come. These include studies ...

Adults with cystic fibrosis experience higher pain prevalence and severity compared to healthy controls, with significant unmet needs in pain management. New study highlights critical gaps in care.

CONCLUSIONS These data support previous findings that deficiency of α 1-AT is not associated with more severe pulmonary disease in cystic fibrosis and may be associated with milder lung disease.